DUBAI, United Arab Emirates, May 2, 2017 /PRNewswire/ -- Nobles Medical Technologies™ II (NMT2) continues to expand its clinical experience in septal repair to include ASD closure. Prof. Anthony Nobles, CEO and Chief Clinical Specialist of NMT2 presented the cases and recent data to at the PICS-AICS in Florida and the CSI Structural Heart Conference in Dubai, AUAE. The well attended congresses, which focus on structural heart in adults, and children showcased the first multi patient data of closure of an ASD without surgery or without the use of a device implanted in the heart. NobleStitch™ was met with overwhelming acceptance as the next generation of treatment for small ASD's. At the CSI Dubai conference, Prof. Nobles shocked the audience with the first ever clinical images and initial follow up data of a patch sewn fully percutaneous to close large ASD's.
Dr. Niels Erik Nielsen, Director of structural heart interventions at Linköping University Hospital, Linköping, Sweden, has performed several of the ASD cases with Prof. Nobles proctoring the new technique.
Dr. Nielsen commented: "We continue to see the expanding indication for the NobleStitch technology, placing only a suture like the surgeon and leaving no implant behind is clearly the future in my eyes. I look forward to the long-term data that I believe will demonstrate this is the best method to close small ASD's. Currently I have already made the NobleStitch™ my primary treatment for PFO closure and I believe in time this will be the same for ASD's."
Prof. Anthony Nobles, CEO, Chief Clinical Specialist of NMT2 and inventor of the NobleStitch™ EL who assisted Dr. Nielsen during the case providing technical support commented, "We are very excited to show this data and the response of the key opinion leaders has been resounding to hear. We are focused on transforming the treatment of these structural heart procedures to be more like surgical outcomes without the surgery and without a large foreign body implant left in the patient."
About Nobles Medical Technology II
Nobles Medical Technology™ II, Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the PFO, ASD-closure, and vascular-suturing marketplace. The company does business under the name of Nobles Medical II (NMT II). Initial efforts of the company are focused on the innovative suture-based PFO closure system for closing the Patent Foramen Ovale (PFO), a tunnel between the right and left atria of the heart.
The NobleStitch™ is approved for PFO Closure and Cardiovascular suturing in the European Union. The NobleStitch™ EL is FDA cleared for vascular and cardiovascular suturing in the United States. NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch, Inc.).
NobleStitch™ EL for PFO closure
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.
For more on Nobles Medical Technologies II visit www.NoblesMed2.com
For more information, please contact shareholder representatives:
P. +1 714 427 6348
F. +1 714 427 6343
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/noblestitch-el-atrial-septal-defect-closure-presented-at-pics-aics-and-csi-dubai-conferences-300449590.html
SOURCE Nobles Medical Technology II, Inc.